Skip to main content
Erschienen in: Endocrine 2/2015

01.03.2015 | Endocrine Genetics/Epigenetics

Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation

verfasst von: Auryan Szalat, Michal Shahar, Shoshana Shpitzen, Boaz Nachmias, Gabriel Munter, David Gillis, Ronen Durst, Dror Mevorach, Eran Leitersdorf, Vardiella Meiner, Haim Rosen

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor with a crucial role in calcium homeostasis. Mutations in the CaSR gene may lead to specific parathyroid disorders due to either gain-of-function (autosomal dominant hypercalciuric hypocalcemia; ADHH) or loss-of-function (familial hypocalciuric hypercalcemia; FHH). Our aim was to evaluate CaSR mutations as a cause of disease in selected patients. We identified and recruited patients with phenotypes suggestive of CaSR-related parathyroid disorders. DNA was extracted, and CaSR gene was sequenced. Live-ratiometric measurements of intracellular [Ca2+] and Western blot assays for evaluation of MAPK phosphorylation in response to changes in extracellular [Ca2+] were performed in transiently transfected HEK-293T cells to functionally characterize mutants. A total of 21 patients were evaluated, seven of them with idiopathic hypoparathyroidism (suspected ADHH) and 14 with hyperparathyroidism (suspected FHH). In the latter group two patients were found to harbor missense mutations: a novel heterozygous I32 V mutation in a female index case and a sporadic known R185Q mutation in a 1-year-old girl. In-vitro functional studies showed that I32 V is an inactivating mutation. In our study, most patients had normal CaSR sequencing. This suggests that phenotypic pitfalls may occur at time of patients’ selection for CaSR sequencing. In one patient with strong positive pre-test probability based on both familial history and appropriate phenotype, a novel I32 V mutation leading to FHH was identified and characterized. In cases of familial parathyroid disorders, CaSR sequencing should be performed, but if negative, one should consider involvement of alternative genes or mechanisms.
Literatur
1.
Zurück zum Zitat N. Chattopadhyay, A. Mithal, E.M. Brown, The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 17(4), 289–307 (1996)PubMed N. Chattopadhyay, A. Mithal, E.M. Brown, The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 17(4), 289–307 (1996)PubMed
2.
Zurück zum Zitat D. Riccardi, E.M. Brown, Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal. Physiol. 298(3), F485–F499 (2009)CrossRefPubMedCentralPubMed D. Riccardi, E.M. Brown, Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal. Physiol. 298(3), F485–F499 (2009)CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat A. Hofer, E. Brown, Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 4(7), 530–538 (2003)CrossRefPubMed A. Hofer, E. Brown, Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 4(7), 530–538 (2003)CrossRefPubMed
4.
Zurück zum Zitat C. Ye, K. Rogers, M. Bai, S.J. Quinn, E.M. Brown, P.M. Vassilev, Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. Biochem. Biophys. Res. Commun. 226(2), 572–579 (1996)CrossRefPubMed C. Ye, K. Rogers, M. Bai, S.J. Quinn, E.M. Brown, P.M. Vassilev, Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. Biochem. Biophys. Res. Commun. 226(2), 572–579 (1996)CrossRefPubMed
5.
Zurück zum Zitat A.L. Magno, B.K. Ward, T. Ratajczak, The calcium-sensing receptor: a molecular perspective. Endocr. Rev. 32(1), 3–30 (2011)CrossRefPubMed A.L. Magno, B.K. Ward, T. Ratajczak, The calcium-sensing receptor: a molecular perspective. Endocr. Rev. 32(1), 3–30 (2011)CrossRefPubMed
6.
Zurück zum Zitat E. Brown, Clinical lessons from the calcium-sensing receptor. Nat. Clin. Pract. Endocrinol. Metab. 3(2), 122–133 (2007)CrossRefPubMed E. Brown, Clinical lessons from the calcium-sensing receptor. Nat. Clin. Pract. Endocrinol. Metab. 3(2), 122–133 (2007)CrossRefPubMed
7.
Zurück zum Zitat M. Yamamoto, T. Akatsu, T. Nagase, E. Ogata, Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85(12), 4583–4591 (2000)CrossRefPubMed M. Yamamoto, T. Akatsu, T. Nagase, E. Ogata, Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85(12), 4583–4591 (2000)CrossRefPubMed
8.
Zurück zum Zitat I.R. Gunn, D. Gaffney, Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. 41(Pt 6), 441–458 (2004)CrossRefPubMed I.R. Gunn, D. Gaffney, Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. 41(Pt 6), 441–458 (2004)CrossRefPubMed
9.
Zurück zum Zitat O. Egbuna, E. Brown, Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 22(1), 129–148 (2008)CrossRefPubMedCentralPubMed O. Egbuna, E. Brown, Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 22(1), 129–148 (2008)CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat J. Varghese, T. Rich, C. Jimenez, Benign familial hypocalciuric hypercalcemia. Endocr. Pract. 17(Suppl 1), 13–17 (2011)CrossRefPubMed J. Varghese, T. Rich, C. Jimenez, Benign familial hypocalciuric hypercalcemia. Endocr. Pract. 17(Suppl 1), 13–17 (2011)CrossRefPubMed
11.
Zurück zum Zitat U. Quitterer, M. Hoffmann, M. Freichel, M.J. Lohse, Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J. Biol. Chem. 276(9), 6763–6769 (2001)CrossRefPubMed U. Quitterer, M. Hoffmann, M. Freichel, M.J. Lohse, Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J. Biol. Chem. 276(9), 6763–6769 (2001)CrossRefPubMed
12.
Zurück zum Zitat S.H. Pearce, M. Bai, S.J. Quinn, O. Kifor, E.M. Brown, R.V. Thakker, Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Investig. 98(8), 1860–1866 (1996)CrossRefPubMedCentralPubMed S.H. Pearce, M. Bai, S.J. Quinn, O. Kifor, E.M. Brown, R.V. Thakker, Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Investig. 98(8), 1860–1866 (1996)CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248–249 (2010)CrossRefPubMedCentralPubMed I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248–249 (2010)CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat J.M. Schwarz, C. Rodelsperger, M. Schuelke, D. Seelow, Mutationtaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7(8), 575–576 (2010)CrossRefPubMed J.M. Schwarz, C. Rodelsperger, M. Schuelke, D. Seelow, Mutationtaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7(8), 575–576 (2010)CrossRefPubMed
15.
Zurück zum Zitat M. Bai, S. Trivedi, E.M. Brown, Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273(36), 23605–23610 (1998)CrossRefPubMed M. Bai, S. Trivedi, E.M. Brown, Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273(36), 23605–23610 (1998)CrossRefPubMed
16.
Zurück zum Zitat M.R. Pollak, E.M. Brown, Y.H. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, T. Levi, C.E. Seidman, J.G. Seidman, Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75(7), 1297–1303 (1993)CrossRefPubMed M.R. Pollak, E.M. Brown, Y.H. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, T. Levi, C.E. Seidman, J.G. Seidman, Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75(7), 1297–1303 (1993)CrossRefPubMed
17.
Zurück zum Zitat H. Heath 3rd, S. Odelberg, C.E. Jackson, B.T. Teh, N. Hayward, C. Larsson, N.R. Buist, K.J. Krapcho, B.C. Hung, I.V. Capuano, J.E. Garrett, M.F. Leppert, Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81(4), 1312–1317 (1996)CrossRefPubMed H. Heath 3rd, S. Odelberg, C.E. Jackson, B.T. Teh, N. Hayward, C. Larsson, N.R. Buist, K.J. Krapcho, B.C. Hung, I.V. Capuano, J.E. Garrett, M.F. Leppert, Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81(4), 1312–1317 (1996)CrossRefPubMed
18.
Zurück zum Zitat B. Obermannova, K. Banghova, Z. Sumnik, H.M. Dvorakova, J. Betka, F. Fencl, S. Kolouskova, O. Cinek, J. Lebl, Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur. J. Pediatr. 168(5), 569–573 (2009)CrossRefPubMed B. Obermannova, K. Banghova, Z. Sumnik, H.M. Dvorakova, J. Betka, F. Fencl, S. Kolouskova, O. Cinek, J. Lebl, Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur. J. Pediatr. 168(5), 569–573 (2009)CrossRefPubMed
19.
Zurück zum Zitat C.M. Reh, G.N. Hendy, D.E. Cole, D.D. Jeandron, Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab. 96(4), E707–E712 (2011)CrossRefPubMed C.M. Reh, G.N. Hendy, D.E. Cole, D.D. Jeandron, Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab. 96(4), E707–E712 (2011)CrossRefPubMed
20.
Zurück zum Zitat M. Bai, S.H. Pearce, O. Kifor, S. Trivedi, U.G. Stauffer, R.V. Thakker, E.M. Brown, B. Steinmann, In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J. Clin. Investig. 99(1), 88–96 (1997)CrossRefPubMedCentralPubMed M. Bai, S.H. Pearce, O. Kifor, S. Trivedi, U.G. Stauffer, R.V. Thakker, E.M. Brown, B. Steinmann, In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J. Clin. Investig. 99(1), 88–96 (1997)CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat S.E. Christensen, P.H. Nissen, P. Vestergaard, L. Heickendorff, K. Brixen, L. Mosekilde, Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin. Endocrinol. (Oxf) 69(5), 713–720 (2008)CrossRef S.E. Christensen, P.H. Nissen, P. Vestergaard, L. Heickendorff, K. Brixen, L. Mosekilde, Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin. Endocrinol. (Oxf) 69(5), 713–720 (2008)CrossRef
22.
Zurück zum Zitat Y.H. Chou, M.R. Pollak, M.L. Brandi, G. Toss, H. Arnqvist, A.B. Atkinson, S.E. Papapoulos, S. Marx, E.M. Brown, J.G. Seidman et al., Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56(5), 1075–1079 (1995)PubMedCentralPubMed Y.H. Chou, M.R. Pollak, M.L. Brandi, G. Toss, H. Arnqvist, A.B. Atkinson, S.E. Papapoulos, S. Marx, E.M. Brown, J.G. Seidman et al., Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56(5), 1075–1079 (1995)PubMedCentralPubMed
23.
Zurück zum Zitat V. Guarnieri, L. Canaff, F.H. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y. Wong, A. Notarangelo, L. D’Agruma, M. Sacco, D.E. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95(4), 1819–1829 (2010)CrossRefPubMed V. Guarnieri, L. Canaff, F.H. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y. Wong, A. Notarangelo, L. D’Agruma, M. Sacco, D.E. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95(4), 1819–1829 (2010)CrossRefPubMed
24.
Zurück zum Zitat S.H. Pearce, D. Trump, C. Wooding, G.M. Besser, S.L. Chew, D.B. Grant, D.A. Heath, I.A. Hughes, C.R. Paterson, M.P. Whyte et al., Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Investig. 96(6), 2683–2692 (1995)CrossRefPubMedCentralPubMed S.H. Pearce, D. Trump, C. Wooding, G.M. Besser, S.L. Chew, D.B. Grant, D.A. Heath, I.A. Hughes, C.R. Paterson, M.P. Whyte et al., Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Investig. 96(6), 2683–2692 (1995)CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat K. Frank-Raue, G. Leidig-Bruckner, C. Haag, E. Schulze, A. Lorenz, H. Schmitz-Winnenthal, F. Raue, Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 75(1), 50–55 (2011)CrossRef K. Frank-Raue, G. Leidig-Bruckner, C. Haag, E. Schulze, A. Lorenz, H. Schmitz-Winnenthal, F. Raue, Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 75(1), 50–55 (2011)CrossRef
26.
Zurück zum Zitat F. Raue, J. Pichl, H.G. Dorr, D. Schnabel, P. Heidemann, G. Hammersen, C. Jaursch-Hancke, R. Santen, C. Schofl, M. Wabitsch, C. Haag, E. Schulze, K. Frank-Raue, Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia-a German survey. Clin. Endocrinol. (Oxf) 75(6), 760–765 (2011)CrossRef F. Raue, J. Pichl, H.G. Dorr, D. Schnabel, P. Heidemann, G. Hammersen, C. Jaursch-Hancke, R. Santen, C. Schofl, M. Wabitsch, C. Haag, E. Schulze, K. Frank-Raue, Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia-a German survey. Clin. Endocrinol. (Oxf) 75(6), 760–765 (2011)CrossRef
27.
Zurück zum Zitat R. Sarin, N. Tomar, D. Ray, N. Gupta, Y.D. Sharma, R. Goswami, Absence of pathogenic calcium sensing receptor mutations in sporadic idiopathic hypoparathyroidism. Clin. Endocrinol. (Oxf) 65(3), 359–363 (2006)CrossRef R. Sarin, N. Tomar, D. Ray, N. Gupta, Y.D. Sharma, R. Goswami, Absence of pathogenic calcium sensing receptor mutations in sporadic idiopathic hypoparathyroidism. Clin. Endocrinol. (Oxf) 65(3), 359–363 (2006)CrossRef
28.
Zurück zum Zitat A. Lienhardt, M. Bai, J. Lagarde, M. Rigaud, Z. Zhang, Y. Jiang, M. Kottler, E. Brown, M. Garabédian, Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J. Clin. Endocrinol. Metab. 86(11), 5313–5323 (2001)CrossRefPubMed A. Lienhardt, M. Bai, J. Lagarde, M. Rigaud, Z. Zhang, Y. Jiang, M. Kottler, E. Brown, M. Garabédian, Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J. Clin. Endocrinol. Metab. 86(11), 5313–5323 (2001)CrossRefPubMed
29.
Zurück zum Zitat R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009)CrossRefPubMed R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009)CrossRefPubMed
30.
Zurück zum Zitat K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, K. Fujieda, Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 87(7), 3068–3073 (2002)CrossRefPubMed K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, K. Fujieda, Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 87(7), 3068–3073 (2002)CrossRefPubMed
31.
Zurück zum Zitat A. Szalat, H. Mazeh, H.R. Freund, Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur. J. Endocrinol. 160(2), 317–323 (2009)CrossRefPubMed A. Szalat, H. Mazeh, H.R. Freund, Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur. J. Endocrinol. 160(2), 317–323 (2009)CrossRefPubMed
32.
Zurück zum Zitat M.A. Nesbit, F.M. Hannan, S.A. Howles, V.N. Babinsky, R.A. Head, T. Cranston, N. Rust, M.R. Hobbs, H. Heath 3rd, R.V. Thakker, Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368(26), 2476–2486 (2013)CrossRefPubMedCentralPubMed M.A. Nesbit, F.M. Hannan, S.A. Howles, V.N. Babinsky, R.A. Head, T. Cranston, N. Rust, M.R. Hobbs, H. Heath 3rd, R.V. Thakker, Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368(26), 2476–2486 (2013)CrossRefPubMedCentralPubMed
33.
Zurück zum Zitat M.A. Nesbit, F.M. Hannan, S.A. Howles, A.A. Reed, T. Cranston, C.E. Thakker, L. Gregory, A.J. Rimmer, N. Rust, U. Graham, P.J. Morrison, S.J. Hunter, M.P. Whyte, G. McVean, D. Buck, R.V. Thakker, Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat. Genet. 45(1), 93–97 (2013)CrossRefPubMedCentralPubMed M.A. Nesbit, F.M. Hannan, S.A. Howles, A.A. Reed, T. Cranston, C.E. Thakker, L. Gregory, A.J. Rimmer, N. Rust, U. Graham, P.J. Morrison, S.J. Hunter, M.P. Whyte, G. McVean, D. Buck, R.V. Thakker, Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat. Genet. 45(1), 93–97 (2013)CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat J.P. Bilezikian, A. Khan, J.T. Potts Jr, M.L. Brandi, B.L. Clarke, D. Shoback, H. Juppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317–2337 (2011)CrossRefPubMedCentralPubMed J.P. Bilezikian, A. Khan, J.T. Potts Jr, M.L. Brandi, B.L. Clarke, D. Shoback, H. Juppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317–2337 (2011)CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat R. Goswami, E. Brown, N. Kochupillai, N. Gupta, R. Rani, O. Kifor, N. Chattopadhyay, Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150(1), 9–18 (2004)CrossRefPubMed R. Goswami, E. Brown, N. Kochupillai, N. Gupta, R. Rani, O. Kifor, N. Chattopadhyay, Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150(1), 9–18 (2004)CrossRefPubMed
36.
Zurück zum Zitat A. Mayer, C. Ploix, J. Orgiazzi, A. Desbos, A. Moreira, H. Vidal, J.C. Monier, J. Bienvenu, N. Fabien, Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J. Clin. Endocrinol. Metab. 89(9), 4484–4488 (2004)CrossRefPubMed A. Mayer, C. Ploix, J. Orgiazzi, A. Desbos, A. Moreira, H. Vidal, J.C. Monier, J. Bienvenu, N. Fabien, Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J. Clin. Endocrinol. Metab. 89(9), 4484–4488 (2004)CrossRefPubMed
37.
Zurück zum Zitat N. Gavalas, E. Kemp, K. Krohn, E. Brown, P. Watson, A. Weetman, The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 92(6), 2107–2114 (2007)CrossRefPubMed N. Gavalas, E. Kemp, K. Krohn, E. Brown, P. Watson, A. Weetman, The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 92(6), 2107–2114 (2007)CrossRefPubMed
38.
Zurück zum Zitat O. Kifor, F.D. Moore Jr, M. Delaney, J. Garber, G.N. Hendy, R. Butters, P. Gao, T.L. Cantor, I. Kifor, E.M. Brown, J. Wysolmerski, A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88(1), 60–72 (2003)CrossRefPubMed O. Kifor, F.D. Moore Jr, M. Delaney, J. Garber, G.N. Hendy, R. Butters, P. Gao, T.L. Cantor, I. Kifor, E.M. Brown, J. Wysolmerski, A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88(1), 60–72 (2003)CrossRefPubMed
39.
Zurück zum Zitat J. Pallais, O. Kifor, Y. Chen, D. Slovik, E. Brown, Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N. Engl. J. Med. 351(4), 362–369 (2004)CrossRefPubMed J. Pallais, O. Kifor, Y. Chen, D. Slovik, E. Brown, Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N. Engl. J. Med. 351(4), 362–369 (2004)CrossRefPubMed
40.
Zurück zum Zitat J.C. Pallais, E.H. Kemp, C. Bergwitz, L. Kantham, D.M. Slovik, A.P. Weetman, E.M. Brown, Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 96(3), 672–680 (2010)CrossRefPubMedCentralPubMed J.C. Pallais, E.H. Kemp, C. Bergwitz, L. Kantham, D.M. Slovik, A.P. Weetman, E.M. Brown, Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 96(3), 672–680 (2010)CrossRefPubMedCentralPubMed
41.
Zurück zum Zitat M. Alimohammadi, P. Björklund, A. Hallgren, N. Pöntynen, G. Szinnai, N. Shikama, M.P. Keller, O. Ekwall, S.A. Kinkel, E.S. Husebye, J. Gustafsson, F. Rorsman, L. Peltonen, C. Betterle, J. Perheentupa, G. Akerström, G. Westin, H.S. Scott, G.A. Holländer, O. Kämpe, Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Eng. J. Med. 358(10), 1018–1028 (2008)CrossRef M. Alimohammadi, P. Björklund, A. Hallgren, N. Pöntynen, G. Szinnai, N. Shikama, M.P. Keller, O. Ekwall, S.A. Kinkel, E.S. Husebye, J. Gustafsson, F. Rorsman, L. Peltonen, C. Betterle, J. Perheentupa, G. Akerström, G. Westin, H.S. Scott, G.A. Holländer, O. Kämpe, Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Eng. J. Med. 358(10), 1018–1028 (2008)CrossRef
42.
Zurück zum Zitat N. Tomar, E. Kaushal, M. Das, N. Gupta, C. Betterle, R. Goswami, Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(4), 1219–1226 (2012)CrossRefPubMed N. Tomar, E. Kaushal, M. Das, N. Gupta, C. Betterle, R. Goswami, Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(4), 1219–1226 (2012)CrossRefPubMed
Metadaten
Titel
Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation
verfasst von
Auryan Szalat
Michal Shahar
Shoshana Shpitzen
Boaz Nachmias
Gabriel Munter
David Gillis
Ronen Durst
Dror Mevorach
Eran Leitersdorf
Vardiella Meiner
Haim Rosen
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0370-3

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.